%0 Journal Article
%T Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.
%A Zheng Z
%A Peng F
%A Zhou Y
%J Chin Med J Pulm Crit Care Med
%V 2
%N 2
%D 2024 Jun
%M 38962100
暂无%R 10.1016/j.pccm.2024.04.003
%X Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a dismal prognosis. Early diagnosis, accurate prognosis, and personalized therapeutic interventions are essential for improving patient outcomes. Biomarkers, as measurable indicators of biological processes or disease states, hold significant promise in IPF management. In recent years, there has been a growing interest in identifying and validating biomarkers for IPF, encompassing various molecular, imaging, and clinical approaches. This review provides an in-depth examination of the current landscape of IPF biomarker research, highlighting their potential applications in disease diagnosis, prognosis, and treatment response. Additionally, the challenges and future perspectives of biomarker integration into clinical practice for precision medicine in IPF are discussed.